WhatsappImmune checkpoint targeted therapy
- identification of new innate and adaptive immune checkpoints
- development of mono and bispecific checkpoint targeting antibodies
- development of DC fusions
Pre-clinical Chimeric Antigen Receptor (CAR) therapy development
- designing novel CAR-T constructs for T and B cell lymphoma and AML
- delineating TME impact on CAR-T in B cell lymphoma
- delineating impact of preconditioning on CAR-T cell activity in B cell lymphoma
- designing alternate CAR effector cell therapies for B and T cell lymphoma
- improve CAR T-cell activation and function by non-lethal irradiation of tumor cells or by applying epigenetic modifiers
Clinical Chimeric Antigen Receptor (CAR) therapy development and translational studies
- perform the phase II non-inferiority HOVON161 trial comparing ARI-0001 CAR-T vs. Yescarta
- set-up and perform phase I CAR-T studies for T or B cell lymphoma
- perform molecular imaging trials to study the behaviour of CAR T-cells and the tumour micro-environment within the patient
- perform smart-tool diagnostic studies for the early detection of CAR T-cell therapy-related adverse events
Targeting the sugar coat of cancer
- identification of cancer glycosylation patterns predicting for therapy resistance
- identification of immune glycosylation patters associating with anti-cancer activity
- implementing glyco-engineering to improve CAR-based therapy